Daily Stock Analysis, AVIR, Aviragen Therapeutics Inc, priceseries

Aviragen Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
0.59
Close
0.59
High
0.60
Low
0.58
Previous Close
0.59
Daily Price Gain
-0.00
YTD High
1.50
YTD High Date
Jan 17, 2017
YTD Low
0.43
YTD Low Date
Jun 2, 2017
YTD Price Change
-0.62
YTD Gain
-51.30%
52 Week High
1.50
52 Week High Date
Jan 17, 2017
52 Week Low
0.43
52 Week Low Date
Jun 2, 2017
52 Week Price Change
-0.74
52 Week Gain
-55.69%
Company Information
Stock Symbol
AVIR
Exchange
NasdaqGS
Company URL
http://www.aviragen.com
Company Phone
301-770-3099
CEO
Joseph M. Patti
Headquarters
-
Business Address
2500 NORTHWINDS PARKWAY, SUITE 100, ALPHARETTA, GEORGIA 30009
Sector
-
Industry Category
-
Industry Group
-
CIK
0000072444
About

Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics, currently being evaluated in ongoing Phase 2b SPIRITUS trial; BTA074, a Phase 2 topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor in Phase 1 development for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment in Phase 2 development for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA.

Description

Aviragen Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of direct-acting antivirals to treat infections worldwide. Its product candidates include vapendavir, which is in Phase IIb SPIRITUS trial for an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA585, an oral fusion protein inhibitor, which is in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, an antiviral treatment that is in Phase II development for condyloma caused by human papillomavirus types 6 and 11. Aviragen Therapeutics, Inc. has collaboration agreement with Daiichi-Sankyo for the development of Laninamivir octanoate, a neuraminidase inhibitor, which has completed Phase II clinical trial for the treatment of influenza. The company was formerly known as Biota Pharmaceuticals, Inc. and changed its name to Aviragen Therapeutics, Inc. in April 2016. Aviragen Therapeutics, Inc. is based in Alpharetta, Georgia.